• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Pembrolizumab after nephrectomy improves survival in renal-cell carcinoma patients

byMinjee Kim
October 13, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter
  1. Patients receiving adjuvant pembrolizumab after nephrectomy for renal-cell carcinoma showed significantly improved disease-free survival compared to patients receiving placebo treatment.
  2. Patients treated with pembrolizumab were shown to have a higher percentage of immune-mediated grade 3 or 4 events compared to patients treated with the placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Patients with locoregional clear-cell renal-cell carcinoma who undergo nephrectomy remain at risk for recurrence after surgery; however, no standard adjuvant treatments are available. Pembrolizumab, an anti-programmed death 1 (PD-1) antibody, is immunotherapy shown to effectively treat advanced renal-cell carcinoma. In this randomized control trial, patients who underwent nephrectomy for renal cell carcinoma and were considered high-risk for recurrence either received 17 cycles of adjuvant pembrolizumab or placebo treatment. The primary measured endpoint was disease-free survival, which was measured from time to first local or distant recurrence, or death of any cause. The study found significantly improved disease-free and overall survival in the group receiving pembrolizumab compared to the placebo. While a higher proportion of patients receiving pembrolizumab experienced severe adverse events, the treatment regimen itself was not associated with any deaths. Together, this phase 3 trial clearly supports the use of pembrolizumab as an adjuvant therapy to nephrectomy in renal-cell carcinoma. The largest limitation to this study was the short follow-up time; therefore, longer intervals are needed to fully assess the effect of adjuvant pembrolizumab on overall survival.

Click to read the study in NEJM

Relevant Reading: Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data

In-Depth [randomized controlled trial]: This open-label, multicenter, phase 3 randomized control trial enrolled 496 patients from 213 sites in 21 countries. Patients who were at least 18 years of age, previously underwent nephrectomy for locoregional clear-cell renal-cell carcinoma, and were considered high-risk for recurrence were included in the study. Patients who received any previous systemic therapy or had not undergone gone surgery were excluded from the study. Participants were randomized in a 1:1 ratio to receive 17 cycles of 200mg adjuvant pembrolizumab or placebo saline treatment, respectively. The primary assessed endpoint was disease-free survival defined as the time of treatment to first local or distant recurrence, or death for any reason. At 24 months, patients receiving pembrolizumab showed significantly improved disease-free survival compared to their placebo counterparts (hazard ratio for recurrence or death [HR], 0.68; 95% confidence interval [CI], 0.53 to 0.87, P=0.002). Pembrolizumab was able to improve the percentage of patients who remained recurrence-free and alive at 24 months (77.3%) compared to the placebo group (68.1%). Patients receiving pembrolizumab also experienced improved overall survival at 96.6% after 24 months compared to 93.5% in the placebo (HR, 0.54; 95%CI, 0.30 to 0.96). No deaths were directly attributable to the treatment regimen. Finally, a greater proportion of immune-mediated adverse events were shown in the pembrolizumab group (34.6%) compared to the placebo group (5.8%). Together, at its first interim analysis, this study supports the use of adjuvant pembrolizumab after partial or complete nephrectomy in patients with clear-cell renal-cell carcinoma.

Image: PD

RELATED REPORTS

#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

Ivonescimab improves survival in advanced non-small cell lung cancer

Transarterial chemoembolization with pembrolizumab and levatinib improves survival in unresectable hepatocellular carcinoma

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: #clear cell carcinoma#clear-cell renal-cell carcinomakidneyNephrectomyPembrolizumabrenal-cell carcinoma
Previous Post

Efficacy and safety of therapeutic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19

Next Post

Adolescent mental health trajectories negatively impacted by the COVID-19 pandemic

RelatedReports

#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
StudyGraphics

#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

July 9, 2025
Lessons from real-world implementation of lung cancer screening
Chronic Disease

Ivonescimab improves survival in advanced non-small cell lung cancer

April 30, 2025
Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified
Chronic Disease

Transarterial chemoembolization with pembrolizumab and levatinib improves survival in unresectable hepatocellular carcinoma

March 5, 2025
Radiographic surrogates may predict tumor-specific survival in renal carcinoma
Pharma

Bristol Myers Squibb: Opdivo-Qvantig is the first FDA approved subcutaneous version of cancer immunotherapy targeting PD-1

February 17, 2025
Next Post
AAP reaffirms support for adolescents’ rights to confidential reproductive care

Adolescent mental health trajectories negatively impacted by the COVID-19 pandemic

#VisualAbstract: Addition of everolimus to letrozole improves survival in patients with HR⁺ breast cancer and disease progression on tamoxifen

#VisualAbstract: Addition of everolimus to letrozole improves survival in patients with HR⁺ breast cancer and disease progression on tamoxifen

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

Utility of D-dimer testing and modified thresholds for ruling out pulmonary embolism in COVID-19 patients

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Structured exercise intervention improves survival in colon cancer patients
  • #VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
  • Cerebral embolic protection does not decrease stroke incidence in TAVI patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.